Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1991 12
1992 21
1993 18
1994 40
1995 41
1996 52
1997 71
1998 99
1999 94
2000 69
2001 86
2002 112
2003 81
2004 83
2005 100
2006 111
2007 110
2008 102
2009 107
2010 131
2011 104
2012 88
2013 115
2014 101
2015 103
2016 129
2017 111
2018 95
2019 102
2020 100
2021 96
2022 74
2023 72
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

2,602 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for advair j
Search for Advait J instead (1 results)
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group. Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing …
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone …
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
Feldman WB, Kesselheim AS, Avorn J, Russo M, Wang SV. Feldman WB, et al. Ann Intern Med. 2023 Aug;176(8):1047-1056. doi: 10.7326/M23-0615. Epub 2023 Aug 8. Ann Intern Med. 2023. PMID: 37549393 Clinical Trial.
The inhaler, Wixela Inhub (fluticasone-salmeterol; Viatris), is a substitutable version of the dry powder inhaler Advair Diskus (fluticasone-salmeterol; GlaxoSmithKline). ...OBJECTIVE: To compare the effectiveness and safety of generic (Wixela I …
The inhaler, Wixela Inhub (fluticasone-salmeterol; Viatris), is a substitutable version of the dry powder inhaler Advair …
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH investigators. Calverley PM, et al. N Engl J Med. 2007 Feb 22;356(8):775-89. doi: 10.1056/NEJMoa063070. N Engl J Med. 2007. PMID: 17314337 Free article. Clinical Trial.
METHODS: We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 microg plus fluticasone propionate at a dose of 500 microg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone …
METHODS: We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 microg plus fluticasone propionate …
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE; GOAL Investigators Group. Bateman ED, et al. Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44. doi: 10.1164/rccm.200401-033OC. Epub 2004 Jul 15. Am J Respir Crit Care Med. 2004. PMID: 15256389 Clinical Trial.
Significantly more patients in each stratum (previously corticosteroid-free, low- and moderate-dose corticosteroid users) achieved control with salmeterol/fluticasone than fluticasone. Total control was achieved across all strata: 520 (31%) versus 326 (19%) p …
Significantly more patients in each stratum (previously corticosteroid-free, low- and moderate-dose corticosteroid users) achieved control w …
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
Nelson HS. Nelson HS. J Allergy Clin Immunol. 2001 Feb;107(2):398-416. doi: 10.1067/mai.2001.112939. J Allergy Clin Immunol. 2001. PMID: 11174215 Review.
In cases of moderate-to-severe persistent asthma, the addition of a second long-term control medication to ICS therapy is one recommended treatment option. A combination-product inhaler (Advair, Seretide) was developed to treat both the inflammatory and bronchoconst …
In cases of moderate-to-severe persistent asthma, the addition of a second long-term control medication to ICS therapy is one recommended tr …
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Chapman KR, et al. Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-339. doi: 10.1164/rccm.201803-0405OC. Am J Respir Crit Care Med. 2018. PMID: 29779416 Free article. Clinical Trial.
METHODS: This 26-week, randomized, double-blind, triple-dummy study assessed the direct change from long-term triple therapy to indacaterol/glycopyrronium (110/50 mug once daily) or continuation of triple therapy (tiotropium [18 mug] once daily plus combination of salme …
METHODS: This 26-week, randomized, double-blind, triple-dummy study assessed the direct change from long-term triple therapy to indacaterol/ …
Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma.
Ng D, Kerwin EM, White MV, Miller SD, Haughie S, Ward JK, Allan R. Ng D, et al. J Aerosol Med Pulm Drug Deliv. 2020 Apr;33(2):99-107. doi: 10.1089/jamp.2019.1547. Epub 2019 Oct 31. J Aerosol Med Pulm Drug Deliv. 2020. PMID: 31634023 Free PMC article. Clinical Trial.
Background: Wixela() Inhub() is a dry powder inhaler approved as a generic equivalent to Advair() Diskus() (fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients with asthma or chronic obstructive pulmonary disease (COPD). This st …
Background: Wixela() Inhub() is a dry powder inhaler approved as a generic equivalent to Advair() Diskus() (fluticasone propio …
Salmeterol-Fluticasone: The Role Revisited.
Vora A, Dhar R, Pinto L, Koul P, Gaonkar P. Vora A, et al. J Assoc Physicians India. 2022 Dec;69(12):11-12. J Assoc Physicians India. 2022. PMID: 35057598
Evidence of eosinophilia (marker of inflammation) in patients with asthma, asthma COPD overlap phenotype or COPD alone should prompt treatment with a combination of inhaled corticosteroids (ICS)/ long-acting beta-agonists (LABA); several studies have shown improvement in t …
Evidence of eosinophilia (marker of inflammation) in patients with asthma, asthma COPD overlap phenotype or COPD alone should prompt treatme …
No association of catastrophic events with Advair.
Yancey SW, Knobil K, Kral K. Yancey SW, et al. Am J Med. 2010 Oct;123(10):e15; author reply e17. doi: 10.1016/j.amjmed.2010.03.029. Am J Med. 2010. PMID: 20920673 No abstract available.
Economic evaluations.
Anthonisen NR. Anthonisen NR. Can Respir J. 2007 Jul-Aug;14(5):264-6. doi: 10.1155/2007/107253. Can Respir J. 2007. PMID: 17874484 Free PMC article. Review. No abstract available.
2,602 results